Luteolin Attenuates Diabetic Nephropathy
                                                  through Suppressing Inflammatory Response and
                                                  Oxidative Stress by Inhibiting STAT3
                                                  Pathway

Miaoyuan Zhang; Liyu He; Jingsong Liu; Lin Zhou

doi:10.1055/a-0998-7985

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(10): 729-739
DOI: 10.1055/a-0998-7985

Article

Luteolin Attenuates Diabetic Nephropathy through Suppressing Inflammatory Response and Oxidative Stress by Inhibiting STAT3 Pathway

Miaoyuan Zhang

²Rehabilitation Department, The Second Xiangya Hospital, Central South University, Changsha, Hunan, PR China

,

Liyu He

¹Nephrology Department, The Second Xiangya Hospital, Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, Hunan, PR China

,

Jingsong Liu

³Department of Nephrology, Chinese Medicine and Western Medicine Hospital Affiliated to Hunan University of Chinese Medicine, Changsha, PR China

,

Lin Zhou

¹Nephrology Department, The Second Xiangya Hospital, Central South University, Key Lab of Kidney Disease and Blood Purification in Hunan, Changsha, Hunan, PR China

› Author Affiliations

Abstract

Background Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). DN has many pathological changes, but tubular injury is considered to be a crucial pathological feature and plays a key role in the progression of DN. Accumulating studies have confirmed that Luteolin (3,4,5,7-tetrahydroxyflavone, Lut) possesses anti-inflammatory and antioxidant activities, which may play a role in kidney protection in DN.

Objectives This paper described the effects of Lut on appropriated tubular injury in the kidneys of db/db mice and searched the possible mechanisms underlying the kidney protection effect in DN.

Methods Twelve-week-old male C57BL/6 J db/db and C57BL/6 J db/m mice were used for the animal experiments. They were organized into the following five groups for the animal experiments: a db/m group (control, n=6); a db/db group(n=8) ; a db/db group receiving Lut (10 mg/kg/day, n=8)treatment by oral gavage; a db/db group receiving stattic (a selective STAT3 inhibitor,50 mg/Kg/day, n=8) treatment by oral gavage and a db/db group receiving both stattic and Lut treatment by oral gavage.

Results In this study, we found that Lut might ameliorate glomerular sclerosis and interstitial fibrosis in DN mouse models through inhibiting the inflammatory response and oxidative stress. And it might play its biological function mainly through repressing the STAT3 activation.

Conclusions Lut attenuates DN mainly via suppression of inflammatory response and oxidative response. STAT3 pathway is the potential target, which ultimately reduces renal fibrosis and delays the progress of DN.

Key words

luteolin - diabetic nephropathy - inflammation - STAT3

Full Text

References

References
1 Xiao L, Xu X, Zhang F. et al. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. Redox Biol 2017; 11: 297-311.
2 Zhou L, Xu DY, Sha WG. et al. Long non-coding RNA MALAT1 interacts with transcription factor Foxo1 to regulate SIRT1 transcription in high glucose-induced HK-2cells injury. Biochem Biophys Res Commun 2018;
3 Zeng LF, Xiao Y, Sun L. A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv Exp Med Biol 2019; 1165: 49-79
4 Chen D, Han S, Zhu Y. et al. Kidney-targeted drug delivery via rhein-loaded polyethyleneglycol-co-polycaprolactone-co-polyethylenimine nanoparticles for diabetic nephropathy therapy. Int J Nanomedicine 2018; 13: 3507-3527
5 Zhan M, Usman I, Yu J. et al. Perturbations in mitochondrial dynamics by p66Shc lead to renal tubular oxidative injury in human diabetic nephropathy. Clin Sci (Lond) 2018; 132: 1297-1314
6 Turkmen K. Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: The four horsemen of the apocalypse. Int Urol Nephrol 2017; 49: 837-844
7 Gupta G, Tiwari J, Dahiya R. et al. Recent updates on neuropharmacological effects of luteolin. Excli J. 2018; 17: 211-214 PubMed PMID: 29743859
8 Domitrovic R, Jakovac H, Tomac J. et al. Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol Appl Pharmacol 2009; 241: 311-321
9 Zhao W, Liang C, Chen Z. et al. Luteolin inhibits proliferation and collagen synthesis of hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2002; 10: 204-206
10 Chen CY, Peng WH, Wu LC. et al. Luteolin ameliorates experimental lung fibrosis both in vivo and in vitro: implications for therapy of lung fibrosis. J Agric Food Chem 2010; 58: 11653-11661
11 Li X, Ma M, Zhang X. et al. Ethanol extract of gardenia fruit alleviates renal interstitial fibrosis induced by unilateral ureteral obstruction in rats. Exp Ther Med 2017; 14: 1381-1388
12 Cummins CB, Wang X, Nunez Lopez O. et al. Luteolin-mediated inhibition of hepatic stellate cell activation via suppression of the STAT3 pathway. Int J Mol Sci 2018;
13 Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol 2018; 225: 342-358
14 Zhang L, Xu X, Yang R. et al. Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling. Drug Des Devel Ther. 2015; 9: 2139-2148
15 Ni J, Shen Y, Wang Z. et al. Inhibition of STAT3 acetylation is associated with angiotesin renal fibrosis in the obstructed kidney. Acta Pharmacol Sin 2014; 35: 1045-1054 PubMed PMID: 24976155
16 Matsui F, Babitz SA, Rhee A. et al. Mesenchymal stem cells protect against obstruction-induced renal fibrosis by decreasing STAT3 activation and STAT3-dependent MMP-9 production. Am J Physiol Renal Physiol 2017; 312: F25-F32
17 Lu TC, Wang ZH, Feng X. et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 2009; 76: 63-71
18 Marchiori C, Scarpa M, Kotsafti A. et al. Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells. J Exp Clin Cancer Res 2019; 38: 190
19 Wang LC, Liao LX, Zhao MB. et al. Protosappanin A exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Chin J Nat Med 2017; 15: 674-679
20 Zhang X, Guo K, Xia F. et al. FGF23(C-tail) improves diabetic nephropathy by attenuating renal fibrosis and inflammation. BMC Biotechnol 2018; 18: 33
21 Liu Z, Liu H, Xiao L. et al. STC-1 ameliorates renal injury in diabetic nephropathy by inhibiting the expression of BNIP3 through the AMPK/SIRT3 pathway. Lab Invest 2019; 99: 684-697
22 Ueda H, Yamazaki C, Yamazaki M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull 2002; 25: 1197-1202
23 Kang OH, Choi JG, Lee JH. et al. Luteolin isolated from the flowers of Lonicera japonica suppresses inflammatory mediator release by blocking NF-kappaB and MAPKs activation pathways in HMC-1 cells. Molecules 2010; 15: 385-398
24 Ou HC, Pandey S, Hung MY. et al. Luteolin: A Natural Flavonoid Enhances the Survival of HUVECs against Oxidative Stress by Modulating AMPK/PKC Pathway. Am J Chin Med 2019; 1-17
25 Jiang ZQ, Li MH, Qin YM. et al. Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of MicroRNA-34a-5p. Int J Mol Sci 2018;
26 Peyser ND, Wang L, Zeng Y. et al. STAT3 as a chemoprevention target in carcinogen-induced head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2016; 9: 657-663
27 Chen X, Wu R, Kong Y. et al. Tanshinone IIA attenuates renal damage in STZ-induced diabetic rats via inhibiting oxidative stress and inflammation. Oncotarget 2017; 8: 31915-31922
28 Wu R, Liu X, Yin J. et al. IL-6 receptor blockade ameliorates diabetic nephropathy via inhibiting inflammasome in mice. Metabolism 2018; 83: 18-24
29 Lin YC, Chang YH, Yang SY. et al. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 2018; 117: 662-675
30 Pezzolesi MG, Poznik GD, Skupien J. et al. An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int 2011; 80: 105-111
31 Pichler R, Afkarian M, Dieter BP. et al. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 2017; 312: F716-F731
32 Zhao M, Han J. Dendrobium officinale kimura et migo ameliorates insulin resistance in rats with diabetic nephropathy. Med Sci Monit Basic Res 2018; 24: 84-92
33 Ribeiro D, Freitas M, Tome SM. et al. Modulation of human neutrophils' oxidative burst by flavonoids. Eur J Med Chem 2013; 67: 280-292
34 Abu-Elsaad N, El-Karef A. The falconoid luteolin mitigates the myocardial inflammatory response induced by high-carbohydrate/high-fat diet in wistar rats. Inflammation 2018; 41: 221-231
35 Kong X, Horiguchi N, Mori M. et al. Cytokines and STATs in liver fibrosis. Front Physiol 2012; 3: 69 3389/fphys.2012.00069
36 Said E, Zaitone SA, Eldosoky M. et al. Nifuroxazide, a STAT3 inhibitor, mitigates inflammatory burden and protects against diabetes-induced nephropathy in rats. Chem Biol Interact 2018; 281: 111-120
37 Li X, Wang Y, Wang K. et al. Renal protective effect of paeoniflorin by inhibition of JAK2/STAT3 signaling pathway in diabetic mice. Biosci Trends 2018; 12: 168-176
38 Yang MY, Wang CJ, Chen NF. et al. Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol Interact 2014; 213: 60-68
39 Aneknan P, Kukongviriyapan V, Prawan A. et al. Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. Asian Pac J Cancer Prev 2014; 15: 5071-5076
40 Huang X, Dai S, Dai J. et al. Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. Onco Targets Ther 2015; 8: 2989-3001